• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.

作者信息

Mehta Neil, Yao Francis Y

机构信息

Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA.

出版信息

Liver Transpl. 2013 Oct;19(10):1055-8. doi: 10.1002/lt.23730.

DOI:10.1002/lt.23730
PMID:23959652
Abstract
摘要

相似文献

1
Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.在选择肝细胞癌患者进行肝移植时，摒弃“一刀切（和单一数字标准）”的做法。
Liver Transpl. 2013 Oct;19(10):1055-8. doi: 10.1002/lt.23730.
2
Predicting the posttransplant prognosis of patients with hepatocellular carcinoma: what lies beneath alpha-fetoprotein?预测肝细胞癌患者移植后的预后：甲胎蛋白背后隐藏着什么？
Liver Transpl. 2013 Oct;19(10):1166-7. doi: 10.1002/lt.23717. Epub 2013 Sep 14.
3
Is there an ideal cutoff for α-fetoprotein as an exclusion criterion for liver transplantation?作为肝移植的排除标准，甲胎蛋白是否存在理想的临界值？
Liver Transpl. 2014 Oct;20(10):1284. doi: 10.1002/lt.23954.
4
α-Fetoprotein and hepatocellular cancer recurrence: a paradigm of the chaos theory.甲胎蛋白与肝细胞癌复发：混沌理论的一个范例
Liver Transpl. 2014 Oct;20(10):1283. doi: 10.1002/lt.23962.
5
Response to letter to the editors.对编辑来信的回复。
Liver Transpl. 2014 Oct;20(10):1285. doi: 10.1002/lt.23982.
6
Survivals after liver transplantation for hepatocellular carcinoma: Granular data for a better allocation process?肝细胞癌肝移植后的生存率：用于优化分配过程的详细数据？
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):374-375. doi: 10.1016/j.hbpd.2018.04.009. Epub 2018 May 24.
7
Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent.接受细胞抑制剂治疗的晚期肝细胞癌患者的甲胎蛋白反应
J Clin Oncol. 2009 Dec 20;27(36):e271; author reply e272. doi: 10.1200/JCO.2009.23.8311. Epub 2009 Nov 16.
8
Expanding transplant criteria for hepatocellular carcinoma: small steps down a long road.扩大肝细胞癌的移植标准：漫长道路上的小步伐。
Hepatology. 2009 Mar;49(3):724-5. doi: 10.1002/hep.22855.
9
Hepatocellular carcinoma metastatic to the ovary: a case report.肝细胞癌转移至卵巢：一例报告
Am J Obstet Gynecol. 1983 Jul 15;146(6):715-7. doi: 10.1016/0002-9378(83)91020-7.
10
[Hepatocarcinoma: a difficult diagnosis].[肝癌：一项困难的诊断]
Gastroenterol Hepatol. 2002 Aug-Sep;25(7):481-2.

引用本文的文献

1
Preoperative assessment of microvascular invasion risk using gadoxetate-enhanced MRI for predicting outcomes after liver transplantation for single hepatocellular carcinoma within the Milan criteria.使用钆塞酸增强 MRI 对米兰标准内单个肝细胞癌进行术前微血管侵犯风险评估，以预测肝移植术后的结局。
Eur Radiol. 2024 Jan;34(1):498-508. doi: 10.1007/s00330-023-09936-y. Epub 2023 Jul 28.
2
AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation.甲胎蛋白对局部区域治疗的反应可对活体肝移植术后肝癌患者的肿瘤复发风险进行分层。
Cancers (Basel). 2023 Mar 1;15(5):1551. doi: 10.3390/cancers15051551.
3
Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
肝癌降期治疗的结果：来自多中心评估肝移植前肿瘤缩小（MERITS-LT）研究联盟的结果。
Gastroenterology. 2021 Nov;161(5):1502-1512. doi: 10.1053/j.gastro.2021.07.033. Epub 2021 Jul 28.
4
A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.一种用于肝细胞癌的新的候补者退出评分 - 确定一个可预测移植后生存状况更差的阈值。
J Hepatol. 2021 Apr;74(4):829-837. doi: 10.1016/j.jhep.2020.10.033. Epub 2020 Nov 11.
5
Hepatocellular Carcinoma-How to Determine Therapeutic Options.肝细胞癌——如何确定治疗方案
Hepatol Commun. 2020 Jan 22;4(3):342-354. doi: 10.1002/hep4.1481. eCollection 2020 Mar.
6
National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.国家在肝移植前对肝细胞癌降期的经验：肿瘤负担、甲胎蛋白和等待时间的影响。
Hepatology. 2020 Mar;71(3):943-954. doi: 10.1002/hep.30879. Epub 2019 Oct 15.
7
Hepatocellular carcinoma treatment: hurdles, advances and prospects.肝细胞癌治疗：障碍、进展与前景
Hepat Oncol. 2018 Sep 28;5(2):HEP08. doi: 10.2217/hep-2018-0002. eCollection 2018 Apr.
8
Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.长等待时间地区肝癌肝移植候补名单中低辍学风险的预测因素：对器官分配的影响。
Am J Transplant. 2019 Aug;19(8):2210-2218. doi: 10.1111/ajt.15353. Epub 2019 Apr 5.
9
Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.甲胎蛋白（AFP）从 > 1000 降至 < 500 ng/mL 的肝癌患者，其移植后结局得到改善。
Hepatology. 2019 Mar;69(3):1193-1205. doi: 10.1002/hep.30413. Epub 2019 Feb 10.
10
When to consider liver transplantation in hepatocellular carcinoma patients?肝细胞癌患者何时应考虑肝移植？
Hepat Oncol. 2017 Jan;4(1):15-24. doi: 10.2217/hep-2016-0010. Epub 2017 Jul 6.